ULTOMIRIS 300MG/30ML(RAVULIZUMAB )

About ULTOMIRIS 300MG/30ML(RAVULIZUMAB )

Ultomiris (ravulizumab-cwvz) infusion is used to treat myasthenia gravis (gMG), hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and neuromyelitis optica spectrum disorder (NMOSD) in certain patients. Ultomiris works by regulating the immune system's response which prevents the body from attacking its cells and helps improve symptoms of myasthenia gravis, PNH, NMOSD, and TMA. Ultomiris is given as an infusion every 4 to 8 weeks as a maintenance dose after initial dosing.

Ultomiris infusion is a long-acting C5 complement inhibitor that works quickly and for a longer time, so patients need less frequent dosing.

Ultomiris FDA approval was granted on December 21, 2018, for PHN after positive results from the study ALXN1210-PNH-301 which show it to have a similar effect using an 8 weekly dose compared to ravulizumab 2 weekly dose. The FDA approval has since been extended to include other specific conditions.

Common side effects of Ultomiris may include:

• fever;
• high blood pressure (hypertension);
• diarrhea, nausea, vomiting;
• headache; or
• cold symptoms such as stuffy nose, sneezing, and sore throat.

Get emergency medical help if you have signs of an allergic reaction with symptoms of hives, difficulty breathing, or swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection. Tell your caregiver if you feel light-headed or if you have chest pain, trouble breathing, or swelling in your face.